Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE

gan Eastell, R., Mitlak, B. H., Wang, Y., Hu, M., Fitzpatrick, L. A., Black, D. M.
Cyhoeddwyd yn Osteoporos Int (2019)

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

gan Watts, N.B., Dore, R.K., Baim, S., Mitlak, B., Hattersley, G., Wang, Y., Rozental, T.D., LeBoff, M.S.
Cyhoeddwyd yn Osteoporos Int (2020)

Tools in the assessment of sarcopenia

gan Cooper, C, Fielding, R, Visser, M, van Loon, LJ, Rolland, Y, Orwoll, E, Reid, K, Boonen, S, Dere, W, Epstein, S, Mitlak, B, Tsouderos, Y, Sayer, AA, Rizzoli, R, Reginster, JY, Kanis, JA
Cyhoeddwyd 2013

Treatment of osteoporosis in men

gan Kaufman, J.-M., Reginster, J.-Y., Boonen, S., Brandi, M. L., Cooper, C., Dere, W., Devogelaer, J.-P., Diez-Perez, A., Kanis, J. A., McCloskey, E., Mitlak, B., Orwoll, E., Ringe, J.D., Weryha, G., Rizzoli, R.
Cyhoeddwyd 2012